Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IMM 2902

Next Previous
X
Search
Drug Profile

IMM 2902

Alternative Names: IMM-2902

Latest Information Update: 21 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ImmuneOnco Biopharma
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD47 antigen inhibitors; ERBB 2 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 30 Oct 2024 ImmuneOnco Biopharmaceuticals terminates a Phase-I clinical trials in Solid tumours (Second-line therapy or greater, Late-stage disease) in USA (IV) due to a business decision resulting in the deprioritization of this project and with no safety concerns present (NCT05076591)
  • 08 Jun 2023 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in China (IV) prior to June 2023 (CXSL2101035)
  • 02 Jun 2023 Efficacy, pharmacokinetics, pharmacodynamics and adverse events data from phase I/II trial in Solid tumours presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top